Introduction
============

Metabolic syndrome is a collection of interrelated cardiovascular risk factors including abdominal obesity, hypertension, glucose intolerance, insulin resistance, and dyslipidemia.[@b1-ijgm-8-203],[@b2-ijgm-8-203] The prevalence of metabolic syndrome appears to be influenced by genetic make-up, being high among Asians compared with white Caucasians for a given total body weight.[@b3-ijgm-8-203],[@b4-ijgm-8-203] Individuals with the metabolic syndrome have significantly higher risk of heart disease (two- to threefold), stroke (twofold), and diabetes (fivefold).[@b5-ijgm-8-203]--[@b7-ijgm-8-203]

Improvement of body composition status, physical performance, cardiovascular factors, and metabolic risk factors is the priority of treatment programs for patients with metabolic syndrome.[@b8-ijgm-8-203]--[@b10-ijgm-8-203] Development of central or visceral fat is consistent with higher risk of metabolic syndrome, while small amounts of weight loss, especially visceral fat, potentially prevent or reverse metabolic syndrome and its deleterious outcomes.[@b11-ijgm-8-203],[@b12-ijgm-8-203] Moreover, a low aerobic exercise capacity appears to be the strongest predictor of metabolic syndrome.[@b13-ijgm-8-203] Indeed, each 1 mL/kg/min increment improvement in VO~2~max was associated with 7% lower risk of metabolic syndrome.[@b14-ijgm-8-203] Furthermore, the muscular strength is generally considered as a function of physical fitness and health. The muscular strength is inversely associated with the prevalence of the metabolic syndrome independently of the aerobic fitness.[@b15-ijgm-8-203] Improvements in other key components of the metabolic syndrome, namely hypertension, glucose intolerance, abnormal lipid profile, and insulin resistance, are mainstay of the non-pharmacological treatment of the metabolic syndrome.[@b16-ijgm-8-203]--[@b18-ijgm-8-203] The lifestyle (behavioral) modification (weight control, diet, exercise, smoking cessation) and aerobic exercise training have been shown to be effective interventions for the prevention and treatment of the metabolic syndrome,[@b19-ijgm-8-203] although with a varying degree of success. Therefore, considering the complex etiology of the metabolic syndrome, we have hypothesized that combination of a multi-targeted aerobic training would be an optimal approach to tackle all the risk factors simultaneously in patients with metabolic syndrome.

Methods
=======

Subject inclusion
-----------------

The study included thirty adult male (54±8 years) subjects with metabolic syndrome according to the definition of the National Cholesterol Education Program Adult Treatment Panel.[@b20-ijgm-8-203] The subjects had three or more of the following criteria: 1) waist circumference \>102 cm, 2) triglycerides ≥150 mg/dL, 3) blood pressure (BP) ≥130.85 mmHg, 4) high-density lipoprotein (HDL) \<40 mg/dL, and 5) fasting glucose ≥110 mg/dL. The baseline characteristics of the participants are outlined in [Table 1](#t1-ijgm-8-203){ref-type="table"}. The inclusion criteria included the ability to undergo training program outlined in the study at Imam Reza University Hospital, Tabriz, Iran. All subjects were informed of the nature, purpose, and potential risks of the study, after which written informed consents were obtained from all participants. All subjects with a history of any form of cardiovascular events (myocardial infarction, transient ischemic attacks, peripheral vascular disease, heart failure, unstable angina, or stroke) were excluded from the study. The study was reviewed and approved by the Institutional Review Board on Human Experiments, Tabriz University of Medicine. Patients were randomized and stratified (by age and body mass index \[BMI\]) into test training group (TTG; n=15) and a control group (CG; n=15). A total of 22 men completed the study (eleven subjects from each group).

Exercise protocol
-----------------

Subjects in TTG performed combined continuous and interval aerobic training as walking and running "uphill" on treadmill three times per week for 16 weeks. Each session consisted of the following: Warm-up for 5 minutes at 50% of maximum heart rate (MHR)Twenty minutes continuous at 70% of MHRTwelve (4×3)-minute intervals at 90% of MHR with a 3-minute active recovery at 70% of MHR between intervalsFive-minute cool-down period at 50% of MHR, giving a total exercise time of 54 minutes.

The subjects in CG continued with their normal daily living activities during the 16 weeks of the study period without any additionally prescribed physical activities.

All subjects were also requested to continue with their normal diet and physical activity patterns outside of the study protocol. Dietary patterns were registered using a "Food Frequency Questionnaire" that has been validated by the Centre for Endocrinology and Metabolism Research of Shahid Beheshti University of Medical Sciences, Tehran, Iran.[@b21-ijgm-8-203]

Data acquisition
----------------

At the start of the study (day 1) and at the end of the weeks 8 and 16, the following measurements were obtained from all participants.

### Anthropometric measurements

The subjects' heights were measured to the nearest 0.1 cm using a wall-mounted Stadiometer (Yagami, Miekosha, Japan), and the body weights were measured to the nearest 0.1 kg using a digital scale (Seca, Germany) with the subjects having only their underwear and being barefooted. BMI was calculated as weight in kilograms divided by the square of the height in meters (kg/m^2^). The waist circumference measurements were taken in triplicate to the nearest 0.1 cm using a nonelastic measuring tape on the skin midway between the iliac crest and the lowest rib in standing position. The percentage body fat was measured using Skinfold Caliper (Yagami) and equations set forth by the American College of Sports Medicine (ACSM),[@b22-ijgm-8-203] for three separate sites: chest pectoral, supra-iliac, and abdominal areas.[@b22-ijgm-8-203] $$\begin{array}{l}
{\%\ \text{body~fat} = (0.39287 \times \text{sum~of~three~skinfolds})} \\
{\mspace{90mu} - (0.00105 \times {\lbrack\text{sum~of~three~skinfolds}\rbrack}^{2})} \\
{\mspace{90mu} + (0.15772 \times \text{age}) - 5.18845} \\
\end{array}$$

### Blood pressure

BP was assessed in duplicate using a manual sphygmomanometer (Riester-1002; Rudolf Reister GmbH, Junginen, Germany) after participants sat quietly for 15 minutes, and the mean of the two measurements was used for statistical analysis.

### Blood analyses

The blood samples were collected from all participants after at least 14 hours of fasting and abstinence from smoking. Furthermore, the participants were asked to abstain from vigorous exercise outside of the study protocol for at least 3 days prior to blood sampling. The serum of blood samples was separated immediately by centrifugation at 3,000 rpm for 10 minutes at 4°C for measurements of insulin, glucose, triacylglycerides, and HDL-cholesterol concentrations. The insulin levels were measured by a radioimmunoassay (using Kit IM3210, Immunotech Company), while glucose concentrations were determined using an automated glucose analyzer (Yellow Springs Instruments (YSI), 2300 STAT). The plasma concentrations of triacylglycerides and HDL were determined by standard enzymatic methods (Roche Diagnostics) on a Hitachi automated spectrophotometer. To estimate overall insulin resistance and insulin sensitivity, the homeostasis assessment model of insulin resistance (HOMA-IR)[@b23-ijgm-8-203] and quantitative insulin sensitivity check index (QUICKI)[@b24-ijgm-8-203] methods were used, respectively. $$\begin{array}{l}
{\text{HOMA-IR} = \lbrack\text{fasting~insulin}(\mu\text{U}/\text{mL})} \\
{\mspace{90mu} \times \ \text{fasting~glucose}(\text{mmol})\rbrack/22.5} \\
\end{array}$$ $$\begin{array}{l}
{\text{QUICKI} = 1/\lbrack\log\text{fasting~insulin}(\mu\text{U}/\text{mL})} \\
{\mspace{90mu} + \log\text{fasting~glucose}(\text{mg}/\text{dL})\rbrack} \\
\end{array}$$

### Cardiopulmonary function test

The cardio-respiratory fitness level was measured during a maximal exercise test on a treadmill (Technogym, Casena, Italy) according to a modified Bruce protocol after a 15-minute warm-up. The BP, heart rate (HR), and the Borg scale of rating of perceived exertion (RPE) were measured at 2 minutes of each stage of the exercise. The test was ended when the subject demanded cessation of the treadmill due to exhaustion, or if the HR achieved was more than 90% of estimated maximal HR (220 -- age), or if the RPE was more than 17. The predictive VO~2~max value was calculated using the ACSM walking equation as outlined below.[@b25-ijgm-8-203] $$\text{VO}_{2} = 0.1\ (\text{speed}) + 1.8\ (\text{speed})(\text{fractional~grade}) + 3.5$$

### Leg strength test (dynamometry assessment)

The subjects performed leg strength test using the back and leg dynamometer. The subjects were asked to stand on the platform with their trunk erected and the knees flexed to an angle of 130°--140°. The subjects then held the hand bar using a pronated grip, positioning it across their thighs by adjusting the length of the chain after which they slowly and gradually were asked to exert as much force as possible while extending their knees without using their back so that the maximum indicator needle remained at the peak force achieved. To ensure reproducibility and accuracy, two or three trials with a 1-minute rest interval were conducted.[@b25-ijgm-8-203]

Statistical analyses
--------------------

Data are presented as mean ± standard deviation. Data were analyzed with a commercially available statistical software program (SPSS version 17.0). The intergroup and intragroup comparisons were assessed using a repeated measure of analysis of variance and post hoc Bonferroni where appropriate. Indicators for group (CG vs TTG), time (in weeks), and an interaction term (group × time) were assessed. Values of *P*\<0.05 are considered as statistically significant.

Results
=======

Baseline characteristics
------------------------

There were no significant differences among the four parameters (body composition, physical performance, cardiovascular factors, and metabolic factors) at baseline between the two groups (CG vs TTG; for all, *P*\>0.05) ([Table 2](#t2-ijgm-8-203){ref-type="table"}). In TTG, four subjects were excluded from the analyses due to their inability to complete the training program; four subjects withdrew from the study (one for a minor sole injury and three for personal reasons). In CG, four patients were excluded from the analyses due to their refusal to perform follow-up tests for personal reasons.

Body composition
----------------

In TTG, the combined training program resulted in significant reductions in total body weight (up to 3.2%), BMI (up to 1.1 kg/m^2^), and waist circumference (up to 3.4 cm) at the end of first 8 weeks, second 8 weeks, and over the 16 weeks after adjusting for the baseline values (all *P*\<0.05). Compared with baseline, there were significant reductions in subcutaneous fat mass at week 16 (up to 3.1%, *P*\<0.05) but not at week 8. Interestingly, in CG, there were no significant changes observed in any of these parameters (for all, *P*\>0.05) ([Table 2](#t2-ijgm-8-203){ref-type="table"}).

Physical performance
--------------------

In TTG, there were significant improvements in maximal oxygen consumption (VO~2~max) by 19.1% and 19.5% at weeks 8 and 16, respectively (for both, *P*\<0.05), compared with their baseline level. However, there were no differences between improvements seen at week 8 and week 16 (*P*\>0.05) ([Table 2](#t2-ijgm-8-203){ref-type="table"}). Compared with baseline levels, the maximum leg strength was significantly improved by 10.04 kg and 22.25 kg at week 8 and week 16 (*P*\<0.05), respectively. Interestingly, the improvement in maximum leg strength was continuous with significant difference between week 8 and week 16 (12.2 kg improvement vs week 8 value, *P*\<0.05) ([Table 2](#t2-ijgm-8-203){ref-type="table"}). There was no significant difference in any physical performance parameters in CG compared with their baseline levels ([Table 2](#t2-ijgm-8-203){ref-type="table"}).

Blood pressure
--------------

In TTG, the combined training program significantly reduced systolic and diastolic BP at week 16 by 12.7 mmHg and 11.9 mmHg (for both, *P*\<0.05), respectively ([Table 2](#t2-ijgm-8-203){ref-type="table"}). Importantly, improvement in BP was evident at week 8 (systolic: 8 mmHg and diastolic: 6 mmHg, *P*\<0.05) ([Table 2](#t2-ijgm-8-203){ref-type="table"}). The reduction in diastolic but not systolic BP during the second 8 weeks was significant compared with the first 8 weeks (week 16: 79.5 mmHg vs week 8: 85.5 mmHg, *P*\<0.05) ([Table 2](#t2-ijgm-8-203){ref-type="table"}). Once again, no significant changes were observed in any of these indices within the CG (*P*\>0.05) ([Table 2](#t2-ijgm-8-203){ref-type="table"}).

Maximal heart rate
------------------

There were no changes in MHR in either TTGs or CGs compared with their baseline characteristics ([Table 2](#t2-ijgm-8-203){ref-type="table"}).

Glycemic and lipid profiles
---------------------------

In TTGs, there were significant (for all, *P*\<0.05) reductions in plasma glucose (−10%: 11.27 mg/dL), insulin (−33%: 5.24 μIU/mL), and triglycerides (−23%: 43 mg/dL) at the end of the study (week 16) compared with their baseline values. Moreover, HOMA-IR values were also reduced in TTG (−1.7 U) indicating improvement in insulin resistance ([Table 2](#t2-ijgm-8-203){ref-type="table"}). Indeed, insulin sensitivity analysis confirmed a significant increase (7%, *P*\<0.05) in TTG at week 8. There was also a numerical increase in plasma HDL concentrations (3.4%: 2 mg/dL) at week 8 in TTGs, but it did not reach statistical significance (*P*\>0.05) level. Interestingly, no further reductions in any of the above biochemical parameters were seen during the second 8 weeks in TTG. In CG, there were no significant changes observed in any of above indices at any stage of the study period ([Table 2](#t2-ijgm-8-203){ref-type="table"}).

Changes in medications
----------------------

At the end of the study period, anti-diabetes medications (sulfonylureas: glibenclamide) but not metformin were reduced by 17.2% (by dosage) in TTG. There were no other changes in medications (lipid-lowering, antihypertensive agents) in either TTGs or CGs. At the end of the experimental period (week 16) in TTG, 54% (six out of eleven patients) could no longer be considered as patients with the metabolic syndrome ([Table 3](#t3-ijgm-8-203){ref-type="table"}). Importantly, these observations were made in the presumed absence of dietary changes during the training period (data not shown).

Discussion
==========

With increasing chronological age, there is a tendency to accumulate excess weight, often with consequentially marked increase in adiposity. Nearly four decades ago, an eloquent study reported that body fat in adults may double between the ages of 20 years and 60 years, resulting in an increased risk for the development of type 2 diabetes mellitus (T2DM) and cardiovascular disease.[@b26-ijgm-8-203] Obesity per se is directly associated with poor cardiovascular outcomes.[@b27-ijgm-8-203],[@b28-ijgm-8-203] Conversely, reductions in adiposity (physiologically, pharmacologically, or surgically) have been shown to improve and in some cases completely reverse T2DM and improve cardiovascular function.[@b29-ijgm-8-203]--[@b31-ijgm-8-203]

In this study, 16-week lifestyle intervention (combined continuous and interval aerobic training program) significantly improved risk factor markers for T2DM (fasting plasma glucose and insulin levels, HOMA-IR, and QUICKI) and cardiovascular risk factors (adiposity, BP, and lipid profile) indicating a clear positive impact of our intervention program in these subjects. Moreover, subjects in TTG patients had significantly improved muscular strength, a finding that can guide us for effective management of fatigue in patients with T2DM. In patients with T2DM, there is a persistent muscular weakness in particular in slow twitch muscles (arms and legs).[@b32-ijgm-8-203] The exact mechanism(s) of this phenomenon is not fully understood yet. However, it is possible that a) persistently high plasma glucose (hyperglycemia) may exert toxic effect (glucotoxicity) on muscle fibers, or b) the diabetes-induced neuropathy may impede optimal muscular function. Alternatively, diabetes-induced endothelial damage may limit oxygen delivery to muscular tissue in T2DM patients, resulting in their decreased performance. Indeed, reductions observed in circulating plasma glucose and insulin as well as increase in VO~2~max in TTG provide plausible arguments for above hypotheses. Other possible explanations may include interference of high level of intramuscular triacylglycerides,[@b33-ijgm-8-203] or alterations in insulin responsiveness of muscle fibers.[@b34-ijgm-8-203] However, further mechanistic studies are required to elucidate the exact mechanism(s) involved in muscular weakness in T2DM.

The most remarkable finding in our study is that improvements observed by our combined continuous and interval aerobic training program were not transient. The program had significant positive effects at week 8 followed by further improvements at week 16, with the exception of plasma glucose and insulin levels. This in turn suggests that biochemical and anthropometric improvement (reduction in % fat, total body weight, waist circumference, BMI, and increased muscular strength) is a continuous flow that could be achieved in proportion to the length and volume of the training program, underlining the need for continuous care program for such patients. In other words, there is a clear evidence indicating susceptibility of the patients' physiological being to adapt to lifestyle (exercise) changes, further underscoring the importance of the diet and exercise regimen in managing sequelaes of obesity and T2DM. In practice, the continuum of care does not exist which may explain our collective failure in managing obesity and T2DM-related health problems.

As mentioned above, there were no significant changes in plasma glucose and insulin levels between week 8 and week 16. The main reason for this apparent stagnation of the metabolic improvement is that after the first 8 weeks, the fasting plasma glucose and insulin levels in TTG were returned to near-normal levels (fasting plasma glucose: 108 mg/dL and insulin: 11 μIU/mL), which suggests that maximum effect has already been reached by 8 weeks of our exercise program. This finding can have major implications in management of patients with prediabetes and T2DM.

The fat tissue provides the required fuel for exercising muscle during an aerobic training period. The triacylglycerides are first hydrolyzed, and the resultant fatty acids are then transported by blood flow and delivered to the mitochondria of working muscle where they are oxidized. Although the lipolytic rate remains relatively high with increasing exercise intensity, the release of fatty acids into the circulation declines suggesting that increasing exercise intensity inhibits fat oxidation by inhibiting the carnitinepalmitoyltransferase 1A and carnitine-mediated transport of fatty acids into mitochondria.[@b35-ijgm-8-203] In fact, it appears that that maximal fat oxidation occurs at around 42%±6% VO~2~max (62%±5% MHR) with average fat oxidation rate of 0.45±0.07 g/min.[@b36-ijgm-8-203] Thus, an exercise training program at an intensity that elicits maximal rates of fat oxidation (ie, Fatmax)[@b37-ijgm-8-203] may be a useful armament in weight loss programs and health-related exercise programs. Interval training markedly increases (2.5- to 15-fold) insulin receptor phosphorylation (and thus activation) in muscle and fat tissue.[@b8-ijgm-8-203] In our study, combined continuous and interval training program improved metabolic syndrome markers (hyperglycemia, hyperinsulinemia, insulin sensitivity, and insulin resistance indexes) which may have contributed to increased fat utilization and metabolism leading to decrease in % fat levels in TTG. Taking together previous reports, it is plausible that there was approximately 20% increase in VO~2~max in TTG pointing to increased rate of fat oxidation, a mechanism which may also have contributed to reduction in adiposity. Therefore, we propose that the "continuous training" could be considered as part of a Fatmax training regimen. However, our finding is in contrast to two previous reports where no significant effect of endurance exercise on body composition indices in metabolic syndrome patients was seen.[@b38-ijgm-8-203],[@b39-ijgm-8-203] These contrasting results may be due to the use of different training equipment and/or patient selection. For instance, both the previous studies[@b38-ijgm-8-203],[@b39-ijgm-8-203] conducted the bulk of their aerobic training on the "cyclo-ergometer" equipment, whereas in this study, the "treadmill" was used during the entire program accounting for reduction in % fat, since the rate of fat oxidation is higher during running than activity on cyclo-ergometer.[@b40-ijgm-8-203]

Metabolic syndrome patients have lower physical fitness levels than healthy individuals.[@b32-ijgm-8-203],[@b41-ijgm-8-203] There appears to be a strong link between physical function and mortality such that improving physical function improves overall mortality rate.[@b42-ijgm-8-203],[@b43-ijgm-8-203] In this study, there was a steady increase (baseline to week 8 and week 8 to week 16) in aerobic power of the lower limb in TTG implying the importance of increased intensity and duration of the overload to achieve optimal leg strength. This steady increase in the maximum leg strength signifies non-saturation index (desensitization) to the volume and intensity of the exercises prescribed in our program. Furthermore, progressive improvement in leg strength seen in our study may be at least in part due to reduction in intramuscular triacylglyceride[@b33-ijgm-8-203] and increase in capillary density, muscle mass, citrate synthetase activity, cellular oxidative capacity, and maximal stroke volume that limits VO~2~max.[@b8-ijgm-8-203],[@b44-ijgm-8-203]

The obese and diabetic patients almost always present with hypertension. The presence of the metabolic syndrome amplifies hypertension-related end-organ damages (eg, cardiac and renal) over and above the potential contribution of each single component of this syndrome.[@b45-ijgm-8-203] These patients are often on a number of pharmacological agents to maintain optimal BP. However, despite the use of polypharmacy, optimal target BP is rarely achieved.[@b45-ijgm-8-203] In this study, there was a progressive BP reduction in TTG at week 8 and week 16 compared to their respective baseline. Although we did not directly measure changes in arterial elasticity or the level of nitric oxide production, it is possible that aerobic exercise increased shear stress (stimulating production of nitric oxide) in the artery, leading to improved arterial endothelial function and subsequent decrease in arterial BP. Furthermore, reduction in plasma insulin level seen at week 8 and week 16 may have removed vasoconstrictor pathway of insulin (via endothelin response) leading to lower arterial BP.[@b45-ijgm-8-203]

In summary, there is a fast and progressive increase in the incidence and prevalence of obesity and metabolic abnormalities (metabolic syndrome). Obese patients with metabolic syndrome are at increased risk of developing diabetes and cardiovascular disease which would result in premature morbidity and mortality. The lifestyle change remains to be the cornerstone of therapy algorithm. However, the most significant challenge in the management of these conditions remains to be the buy-in from the patients for adequate lifestyle changes. We have shown in this study that a relatively modest but persistent lifestyle change (a programmed exercise regime) would result in improvements in body composition, physical performance, cardiovascular factors, and metabolic factors to an extent of disease reversal in some patients. Therefore, the findings from our study indicate that a "combined continuous and interval aerobic training" could offer an optimal non-pharmacological tool in management of risk factors in patients with metabolic syndrome.
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###### 

Baseline characteristics of subjects enrolled in this study

  Parameters                             Control group   Training test group
  -------------------------------------- --------------- ---------------------
  Physiological (mean ± SD)                              
   Age (years)                           52.8±9.5        54.5±7.8
   Weight (kg)                           97.1±13.1       99.3±14.8
   Waist (cm)                            110.0±6.5       112.5±9.4
   Body mass index (kg/m^2^)             33.8±3.7        34.7±3.6
  **Subjects with diagnosed diabetes**                   
  Medications (n)                                        
   Glibenclamide                         3               3
   Metformin                             3               2
   Statins                               2               2
   Angiotensin II blockers               2               1
   β-Blockers                            3               1

###### 

Parameters related to the metabolic syndrome before, in the middle of, and after the experimental period

  Parameters                         Control group   Test training group                                                                                           
  ---------------------------------- --------------- --------------------- -------------- -------------- --------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Body composition                                                                                                                                                 
   Weight (kg)                       97.18±13.10     97.61±13.10           97.73±13.10    99.30±14.80    97.47±15.50[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}    96.09±15.10[\*](#tfn2-ijgm-8-203){ref-type="table-fn"},[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Body mass index (kg/m^2^)         33.85±3.70      34.01±3.70            34.05±3.70     34.70±3.60     34.04±3.90[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}     33.56±3.80[\*](#tfn2-ijgm-8-203){ref-type="table-fn"},[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Waist circumference (cm)          110.04±6.50     110.09±6.60           110.18±6.50    112.59±9.40    110.95±9.50[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}    109.15±8.80[\*](#tfn2-ijgm-8-203){ref-type="table-fn"},[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Fat (%)                           32.11±5.50      32.48±5.90            32.48±5.80     33.24±4.30     31.45±5.00                                                30.10±4.90[\*](#tfn2-ijgm-8-203){ref-type="table-fn"},[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
  Physical function                                                                                                                                                
   VO~2~max (mL/kg/min)              23.35±2.50      23.54±2.70            23.74±2.80     25.02±3.70     29.80±5.12[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}     29.91±5.10[†](#tfn3-ijgm-8-203){ref-type="table-fn"},[‡](#tfn4-ijgm-8-203){ref-type="table-fn"}
   Leg strength (kg)                 92.77±30.20     93.60±29.30           94.14±29.10    96.61±24.60    106.66±21.56[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}   118.87±24[\*](#tfn2-ijgm-8-203){ref-type="table-fn"},[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
  Cardiovascular factors                                                                                                                                           
   Systolic BP (mmHg)                141.36±17.20    141.45±16.50          142.09±16.90   138.81±13.90   130.09±15.20[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}   126.09±18.70[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Diastolic BP (mmHg)               89.54±7.40      90.36±7.10            89.72±7.60     91.45±7.20     85.45±7.50[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}     79.54±8.70[\*](#tfn2-ijgm-8-203){ref-type="table-fn"},[†](#tfn3-ijgm-8-203){ref-type="table-fn"},[‡](#tfn4-ijgm-8-203){ref-type="table-fn"}
   Mean arterial BP (mmHg)           106.81±9.80     107.39±9.30           106.87±9.60    107.11±8.10    100.33±90[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}      95.05±11.70[\*](#tfn2-ijgm-8-203){ref-type="table-fn"},[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Maximal heart rate (bpm)          160.09±11.10    160.9±11              161±11.30      166.54±9.30    167.18±9.40                                               167.09±9.70
  Metabolic factors                                                                                                                                                
   Fasting plasma insulin (μIU/mL)   15.19±5.70      15.05±5.60            15.05±5.60     15.89±7.50     11.36±4.70[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}     10.65±4.50[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Fasting plasma glucose (mg/dL)    119.54±19.30    119.63±19.40          119.36±19.20   117.72±18.50   108.81±15.50[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}   106±10.70[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Insulin resistance (HOMA-IR)      4.41±1.70       4.38±1.70             4.4±1.70       4.5±20         3.05±1.40[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}      2.8±1.20[†](#tfn3-ijgm-8-203){ref-type="table-fn"}
   Insulin sensitivity (QUICKI)      0.30±0.01       0.30±0.01             0.30±0.01      0.30±0.02      0.32±0.02[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}      0.32±0.02[†](#tfn3-ijgm-8-203){ref-type="table-fn"},[‡](#tfn4-ijgm-8-203){ref-type="table-fn"}
   HDL (mg/dL)                       34.72±5.90      34.81±5.90            34.72±6.00     34.18±5.20     34.27±5.20                                                35.36±5.30
   Triglycerides (mg/dL)             193.45±53.80    193.54±53.90          193.81±50.60   190.54±41.3    162.36±41.90[\*](#tfn2-ijgm-8-203){ref-type="table-fn"}   147.09±37.80[†](#tfn3-ijgm-8-203){ref-type="table-fn"}

**Notes:** Data are mean ± standard error.

Significantly different within each group: baseline (day 1) vs week 8 or week 8 vs week 16 (*P*\<0.05);

significantly different within each group: baseline (day 1) vs week 16 (*P*\<0.05);

significantly different between training group and control group (*P*\<0.05).

**Abbreviations:** BP, blood pressure; HOMA-IR, homeostasis assessment model of insulin resistance; QUICKI, quantitative insulin sensitivity check index; HDL, high-density lipoprotein.

###### 

Number of patients with metabolic syndrome according to ATP III definition at day 1 (baseline), week 8, and week 16 of the study period

  Number of patients and factors                                                   Control group   Test training group                           
  -------------------------------------------------------------------------------- --------------- --------------------- ------- ------- ------- ------
  Average number of metabolic syndrome factors                                     3.9             3.81                  3.81    4       3.36    2.72
  Patients with metabolic syndrome, n[\*](#tfn6-ijgm-8-203){ref-type="table-fn"}   11/11           10/11                 10/11   11/11   8/11    5/11
  Waist circumference, n[\*](#tfn6-ijgm-8-203){ref-type="table-fn"}                11/11           10/11                 11/11   9/11    8/11    8/11
  Fasting glucose, n[\*](#tfn6-ijgm-8-203){ref-type="table-fn"}                    7/11            7/11                  6/11    7/11    4/11    4/11
  High-density lipoprotein, n[\*](#tfn6-ijgm-8-203){ref-type="table-fn"}           9/11            9/11                  9/11    10/11   10/11   9/11
  Triglycerides, n[\*](#tfn6-ijgm-8-203){ref-type="table-fn"}                      8/11            8/11                  8/11    10/11   8/11    6/11
  Blood pressure, n[\*](#tfn6-ijgm-8-203){ref-type="table-fn"}                     8/11            8/11                  8/11    8/11    7/11    3/11

**Notes:**

The first number is the number of patients of whom data was obtained, and the second number is the total number of patients in that study group.

**Abbreviation:** ATP, Adult Treatment Panel.
